Coverage Resumed on Developer of 'Drug Candidate with Blockbuster Potential'
Source: Streetwise Reports
January 24, 2018 (Investorideas.com Newswire) André Uddin, an analyst with Mackie Research Capital Corp., shared his thesis for investing in this biotech.
In a Jan. 18 research note, Uddin reported that Mackie Research Capital Corp. is resuming coverage of BELLUS Health Inc. (BLU:TSX; BLUSF:OTCPK) with a Speculative Buy rating and a CA$1 per share target price. The stock currently is trading at around CA$0.41 per share.
BELLUS is developing BLU-5937, "a best-in-class cough drug candidate with blockbuster potential," Uddin noted. He added that chronic cough constitutes a largely unmet medical need, affecting up to 10%, or 27.5 million (27.5M), adults in the United States. Further, no new therapeutics for this condition have successfully come to the market in 50 years. "We believe BELLUS should be able to monetize this asset after Phase 2 trials and recommend investors take advantage of the share price weakness."
Compared to the potential competitors, BLU-5937 should have greater efficacy and minimal to no adverse side effects. Like BLU-5937, Merck's CA$1.25 billion (CA$1.25B) drug candidate MK-7264, for instance, inhibits P2X3 receptors involved in cough and "showed strong efficacy in reducing cough frequency," Uddin described. However, the drug causes taste loss in patients, likely due to MK-7264's partial binding to P2X2/3 receptors. BLU-5937, in contrast, is "carefully designed to selectively bind P2X3 receptors while avoiding P2X2/3 binding."
The analyst purported that "with a potentially superior profile, BLU-5937 could be the leader in this billion-dollar new class of drugs. Head-to-head animal studies between BLU-5937 and MK-7264 have shown BLU-5937 to be as effective in cough suppression without the taste loss side effect."
Also favorable to the BELLUS story are its experienced leadership and 35% insider ownership. Two of the corporation's executives, chairman Dr. Francesco Bellini and CEO Roberto Bellini, have "completed three successful exits: Biochem Pharma ($6B in 2001), Virochem Pharma ($500M in 2009) and FB Health ($45M in 2017)," Uddin indicated. Bellini, BELLUS' CEO since 2009, is primarily focused on creating shareholder value.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
Disclosures from Mackie Research Capital Corp., Bellus Health Inc., Initiating Coverage, Jan. 18, 2018
RELEVANT DISCLOSURES APPLICABLE TO COMPANIES UNDER COVERAGE:
Relevant disclosures required under IIROC Rule 3400 applicable to companies under coverage discussed in this research report are available on our web site at www.mackieresearch.com.
I, Andre Uddin, certify the views expressed in this report were formed by my review of relevant company data and industry investigation, and accurately reflect my opinion about the investment merits of the securities mentioned in the report. I also certify that my compensation is not related to specific recommendations or views expressed in this report.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.